DACT1 and type 2 diabetes mellitus: Taken together, our findings suggest a possible mechanistic link whereby miR-425-5p, upregulated by SGLT2i treatment, could contribute to reducing visceral adiposity in T2D patients by suppressing adipocyte differentiation and lipogenesis through targeting DACT1.